目的 研究盐酸坦洛新缓释胶囊的制备工艺并对其体外释放度进行考察。方法 采用蔗糖空白丸芯作为载药基质,用苏丽丝和雅克宜作为包衣缓释材料、以羟丙甲纤维素E6作为致孔剂,用流化床底喷溶液上药法制备载药微丸,并进行缓释包衣。以释放度作为评价指标,通过单因素实验对处方影响因素进行考察,并对自制盐酸坦洛新缓释胶囊与市售制剂释放曲线进行比较。结果 本试验所述制剂工艺可靠,能顺利制备盐酸坦洛新缓释胶囊,其体外释放与市售制剂相似,批间及批内重复性较好。结论 本试验制得的盐酸坦洛新缓释胶囊具有良好的缓释效果,制备工艺合理,简单易行,可适合工业化生产。
Abstract
OBJECTIVE To study the preparation technology of tamsulosion hydrochloride sustained-release capsules and investigate the release degree in vitro. METHODS The pellets containing tamsulosin hydrochloride were prepeared in the fluid-bed using bottom gush medicine. Then, it was coated with ethylcellulose aqueous dispersion (surelease), and in the following procedures, water-based acrylic resin enteric system(Acryl-EZE?) was used as coating material, hydroxypropylmethylcellulose E6(HPMC E6) was considered as porous agent by fluid-bed. Based on the release degree in vitro, prescription influence factors were evaluated,as well as drug releases curve was compared, according to the single factor experiment. RESULTS The preparation technology referred in our research was available to make tamsulosin hydrochloride sustained-release capsules, and drug release curve of self-made sustained-release capsules was similar to the commercial one. Additionally, the products reproducibility of intra-batch and inter-batch was excellent. CONCLUSION The tamsulosin hydrochloride sustained-release capsules prepared in this study exhibited ideal sustained-release characteristics in vitro. The formulation is reasonable and feasible.It is suitable for industrial production.
关键词
盐酸坦洛新 /
缓释胶囊 /
制剂处方工艺 /
缓释微丸 /
体外释放
{{custom_keyword}} /
Key words
tamsulosin hydrochloride /
sustained-release capsule /
pharmaceutical technology /
sustained-release pellets /
release in vitro
{{custom_keyword}} /
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] MICHEL M C,KORSTANIE C S, KRAUWINKEL W,et al. Comparison of vascular αl-adrenoceptor antagonism of tamsulosin in oral controlled absorption system(OCAS)and modified release(MR) formulations[J]. Eur Urol Suppl,2005,4(2):45-52.
[2] HONDA K,NAKAGAWA C. Alpha21 adrenoceptor antagonist effects of the optical isomers of YM212617 in rabbit lower urinary tract and prostate[J]. Pharmacol Exp Ther,1986, 239(2):512.
[3] O’ LEARY M P. Tamsulosin current clinical experience[J]. Urol Suppl,2001,58 (6) :42-48.
[4] LEPOR H, AUERBACH S,PARAS BAEZ A,et al. A randomized place-bo-controlled mlticenter study of the efficacy and safety of harnal in the treatment of begnign prostatic hypertetasia [J]. Jurol,1992, 148: 146.
[5] LIU L H,WANG P,LI H Z. The progress in researching of determination of plasma concentration of tamsulosion hydrochloride and its pharmacokinetic[J]. Chin Pharm J(中国药学杂志),2003,38(7):488-490.
[6] MICHEL M C,KORSTANIE C, KRAUWINKEL W, et al. Cardiovascular safety of the oral controlled absorption system(OCAS) formulation of tamsulosin compared to the modified release (MR) formulation [J]. Eur Urol Suppl,2005,4(2):53-60.
[7] LI Q X, QU X W, YUAN G Y. The clinic research of Tonglongqibi(TLQB) soup in treating benign prostatic hyperplasia[J]. China Chin Med(中华中医药学刊),2011,29(6):1441-1443.
[8] SAFARINEJAD M R. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older [J]. Int Urol Nephrol,2008,40(4):921-931.
[9] ZHANG G Y, LIANG X M, WANG R W. Effect and cost-effectiveness analysis of two kinds of tamsulosin for treating benign prostatic hyperplasia[J]. China Pharm(中国药业),2012,21(17):40-41.
[10] National Drug Standards(国家药品标准). WS1-(X-333)-2003, tamsulosion hydrochloride sustained-release capsules [S]. 2003:43-45.
[11] DU C, WANG Y, YANG B, et al. Comparison and application of six similarity evaluation methods of release profiles in felodipine sustained tablets[J]. Chin J Pharm(中国药剂学杂志),2013,11(4):78-83.
[12] SHAH V P,TSONG Y, SATHE P, et al. In vitro dissolution profile comparison—statistics and analysis of the similarity factors f2 [J]. Pharm Res,1998,15(6):889-894.
[13] FDA. FDA guidance for industry dissolution testing of immediate release solid dosage[S]. 1997:8.
[14] XIE M F. The introduce about the project of drug quality's re-evaluation in Japan(series one of the dissolution study)[J]. Drug stand China(中国药品标准),2005,6(6):42-46.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1232 KB)
